Advances in Asymmetric Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advances in Asymmetric Synthesis
Researchers forward approaches for catalytic hydroformylation, asymmetric hydrogenation, and biocatalysis to achieve enantioselectivity.


Pharmaceutical Technology



Figure 3: Comparison of the hydroformylation route (left) to β-siloxyisobutraldehyde with conversion of the Roche ester (right) (6). (UNIVERSITY OF WISCONSIN-MADISON)
"Because the synthetic versatility of aldehydes is so great, enantioselective hydroformylation could be a key step in the synthesis of many pharmaceutical building blocks," says Landis. The synthesis of β-siloxyisobutyraldehyde, a key starting material for polyketide syntheses, shows the opportunities provided by enantioselective hydroformylation (6). As shown in Figure 3, the traditional synthesis of β-siloxyisobutyraldehyde (6) begins with an expensive Roche ester and, in three steps, converts the acid to an aldehyde. The hydroformylation route, in contrast, begins with a commodity chemical, allyl alcohol, and converts it into the desired product in a two-step process, the second of which generates no byproducts that must be separated and disposed.

"Preliminary results in my group demonstrate that the hydroformylation step can be effected with high enantioselectivity (97% enantiomeric excess) and high rates (10,000 catalyst turnovers/h), making hydroformylation a vast improvement over traditional synthesis," says Landis. "Should hydroformylation prove similarly effective for other functionalized alkene substrates, the barrier to the application of enantioselective hydroformylation technology will shift from catalyst performance to incorporating chiral aldehydes into retrosynthetic thought processes when devising new syntheses," he adds.

Asymmetric hydrogentation


Upcoming conferences on chirality
While a catalyst selection is crucial in an asymmetric reaction, so is the choice of the substrate, an approach researchers at Sepracor (Marlborough, MA) showed in making an enamide substrate for asymmetric hydrogenation for the large-scale stereoselective process for (1R, 4S)-trans-norsertraline, a chiral amine structurally similar to sertraline, the API in Pfizer's (New York) "Zoloft."

"Our first approach used to produce kilogram quantities of clinical study material began with (S)-tetralone and a chiral auxiliary (R)-tert-butylsulfinamide," outlines Surenda Singh, research fellow at Sepracor. Singh also spoke at Chiral USA. "The synthesis was very quick to develop and was scaled up to produce ~5 kg of API in >50% overall yield" (17).

Sepracor, however, wanted a more efficient and economical process for larger-scale commercial applications. "After an extensive route-scouting effort, we selected the approach of catalytic asymmetric hydrogenation of the enamide," says Singh. Initial in-house catalyst screening efforts resulted in identification of R,R-Me-BPE-Rh(COD)BF4, a commercially available catalyst. Later in collaboration with Dowpharma another catalyst, Norphos, was identified. "Once we identified the multiple catalysts," says Singh, "we were then faced with two new challenges on how to make the enamide approach a scalable process: availability of limited methods for an efficient synthesis of enamides, and as one would expect, the hydrolysis of the resulting chiral amide did not prove to be a trivial task."

"Fortunately, we were able to solve both of these issues for our substrate, and in a short time developed novel chemistries for the efficient synthesis of enamides and also for the facile cleavage of chiral acetamides," says Singh. The process was scaled up to produce more than 50 kg of API in 63% overall yield and in 99.9% chiral purity with total impurities of < 0.05 A% by high-performance liquid chromatography.

Biocatalysis in asymmetric reactions


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here